$ZIVO
Zivo Bioscience, Inc. Stock $zivo

$zivo Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000165495423010769 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$11.80K	$4.050K	$0.00
YoY Change
Cost Of Revenue	$7.670K	$701.00	$0.00
YoY Change
Gross Profit	$4.130K	$3.349K	$0.00
YoY Change
Gross Profit Margin	35.0%	82.69%
Selling, General & Admin	$1.360M	$1.385M	$1.630M
YoY Change	-2.65%	-15.0%	27.16%
% of Gross Profit	32929.78%	41358.61%
Research & Development	$220.7K	$442.1K	$438.0K
YoY Change	-63.41%	0.93%	-6.38%
% of Gross Profit	5342.69%	13201.34%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.577M	$1.827M	$2.068M
YoY Change	-21.18%	-11.63%	18.19%
Operating Profit	-$1.572M	-$1.824M	-$2.068M
YoY Change	-21.38%	-11.79%	18.19%
Interest Expense	$32.74K	$31.79K	$4.238K
YoY Change	671.17%	650.19%	-77.19%
% of Operating Profit
Other Income/Expense, Net	$252.5K	$246.7K	$4.238K
YoY Change	-6048.98%	5721.28%	-95.6%
Pretax Income	-$1.820M	-$2.071M	-$2.072M
YoY Change	-9.2%	-0.06%	12.26%
Income Tax
% Of Pretax Income
Net Earnings	-$1.825M	-$2.071M	-$2.072M
YoY Change	-8.95%	-0.06%	12.26%
Net Earnings / Revenue	-15465.44%	-51125.23%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.05	-$0.22	-$219.9K
COMMON SHARES
Basic Shares Outstanding	10.45M shares	9.420M shares	9.420M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.480M	$21.07K	$5.084M
YoY Change	-56.29%	-99.59%	-53.37%
Cash & Equivalents	$1.485M	$21.07K	$5.084M
Short-Term Investments
Other Short-Term Assets	$460.0K	$509.0K	$517.1K
YoY Change	34.28%	-1.57%	226.01%
Inventory
Prepaid Expenses
Receivables	$0.00
Other Receivables	$0.00
Total Short-Term Assets	$1.948M	$530.1K	$5.601M
YoY Change	-47.76%	-90.54%	-49.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00	$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$154.2K	$180.3K	$263.8K
YoY Change	-36.51%	-31.66%	531.98%
TOTAL ASSETS
Total Short-Term Assets	$1.948M	$530.1K	$5.601M
Total Long-Term Assets	$154.2K	$180.3K	$263.8K
Total Assets	$2.102M	$710.3K	$5.865M
YoY Change	-47.07%	-87.89%	-47.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$643.8K	$1.273M	$407.8K
YoY Change	6.07%	212.24%	-55.59%
Accrued Expenses	$823.8K	$681.9K	$631.9K
YoY Change	125.81%	7.92%	137.18%
Deferred Revenue
YoY Change
Short-Term Debt	$1.130M	$1.112M	$349.2K
YoY Change	708.93%	218.36%	449.95%
Long-Term Debt Due	$240.0K	$240.0K	$240.0K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$3.174M	$3.804M	$2.697M
YoY Change	37.1%	41.05%	-25.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$20.00K	$50.92K	$157.0K
YoY Change	-84.84%	-67.57%	2239.79%
Total Long-Term Liabilities	$22.03K	$50.92K	$157.0K
YoY Change	-83.3%	-67.57%	22.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.174M	$3.804M	$2.697M
Total Long-Term Liabilities	$22.03K	$50.92K	$157.0K
Total Liabilities	$3.196M	$3.855M	$2.854M
YoY Change	30.61%	35.07%	-24.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$121.7M	-$119.8M	-$112.3M
YoY Change	7.52%	6.7%	8.92%
Common Stock	$1.742K	$9.420K	$9.420K
YoY Change	-81.51%	0.0%	3.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.094M	-$3.145M	$3.010M
YoY Change
Total Liabilities & Shareholders Equity	$2.102M	$710.3K	$5.865M
YoY Change	-47.07%	-87.89%	-47.18%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$1.825M	-$2.071M	-$2.072M
YoY Change	-8.95%	-0.06%	12.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.970M	-$985.7K	-$1.306M
YoY Change	32.37%	-24.51%	-36.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.430M	798.1K	-209.5K
YoY Change	-1737.0%	-480.9%	-101.65%
NET CHANGE
Cash From Operating Activities	-1.970M	-985.7K	-1.306M
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	3.430M	798.1K	-209.5K
Net Change In Cash	1.460M	-187.5K	-1.515M
YoY Change	-186.0%	-87.62%	-114.2%
FREE CASH FLOW
Cash From Operating Activities	-$1.970M	-$985.7K	-$1.306M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10449660	shares
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21067	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1799263	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	509008	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	102416	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	530075	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1901679	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	2956	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001101026
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9419660	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9419660	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40449
	dei	Entity Registrant Name EntityRegistrantName	Zivo Bioscience, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0699977
	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 E. Long Lake Road, Suite 100
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bloomfield Hills
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48304
	dei	City Area Code CityAreaCode	248
	dei	Local Phone Number LocalPhoneNumber	452 9866
	dei	Security12b Title Security12bTitle	Common Stock, par value
	dei	Trading Symbol TradingSymbol	ZIVO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	145241	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	189282	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	32058	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	32058	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	177299	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	221340	usd
CY2023Q2	us-gaap	Assets Assets	710330	usd
CY2022Q4	us-gaap	Assets Assets	2123019	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1273437	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	490670	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	106687	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99259	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	240000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	240000	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	200141	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	525904	usd
CY2023Q2	zivo	Deferred Rd Obligations Participation Agreements Related Parties DeferredRDObligationsParticipationAgreementsRelatedParties	66762	usd
CY2022Q4	zivo	Deferred Rd Obligations Participation Agreements Related Parties DeferredRDObligationsParticipationAgreementsRelatedParties	175427	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	1111765	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	0	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	123540	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	98286	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	681910	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	398176	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3804242	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2027722	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50920	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	105919	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	50920	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	105919	usd
CY2023Q2	us-gaap	Liabilities Liabilities	3855162	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2133641	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9419660	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9419660	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	9420	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	9420	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	116693992	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	115784488	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119848244	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115804530	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3144832	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10622	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	710330	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2123019	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4050	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4050	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q2	us-gaap	Revenues Revenues	4050	usd
CY2022Q2	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	4050	usd
	us-gaap	Revenues Revenues	0	usd
CY2023Q2	us-gaap	Other Restructuring Costs OtherRestructuringCosts	701	usd
CY2022Q2	us-gaap	Other Restructuring Costs OtherRestructuringCosts	0	usd
	us-gaap	Other Restructuring Costs OtherRestructuringCosts	701	usd
	us-gaap	Other Restructuring Costs OtherRestructuringCosts	0	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	701	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	701	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	3349	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	0	usd
	us-gaap	Gross Profit GrossProfit	3349	usd
	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1385102	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1629553	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2953478	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2976295	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	442113	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	438048	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	843910	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1117821	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1827215	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2067601	usd
	us-gaap	Operating Expenses OperatingExpenses	3797388	usd
	us-gaap	Operating Expenses OperatingExpenses	4094116	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1823866	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2067601	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3794039	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4094116	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	31793	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	4238	usd
	us-gaap	Interest Expense InterestExpense	34762	usd
	us-gaap	Interest Expense InterestExpense	6043	usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q2	us-gaap	Other Expenses OtherExpenses	246706	usd
CY2022Q2	us-gaap	Other Expenses OtherExpenses	4238	usd
	us-gaap	Other Expenses OtherExpenses	249675	usd
	us-gaap	Other Expenses OtherExpenses	6043	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2070572	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2071839	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4043714	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4100159	usd
CY2023Q2	zivo	Basic And Diluted Net Income Loss Per Share BasicAndDilutedNetIncomeLossPerShare	-0.22
CY2022Q2	zivo	Basic And Diluted Net Income Loss Per Share BasicAndDilutedNetIncomeLossPerShare	-0.22
	zivo	Basic And Diluted Net Income Loss Per Share BasicAndDilutedNetIncomeLossPerShare	-0.43
	zivo	Basic And Diluted Net Income Loss Per Share BasicAndDilutedNetIncomeLossPerShare	-0.44
CY2023Q2	zivo	Weighted Average Stock Basic And Diluted Shares Outstanding WeightedAverageStockBasicAndDilutedSharesOutstanding	9419660	shares
CY2022Q2	zivo	Weighted Average Stock Basic And Diluted Shares Outstanding WeightedAverageStockBasicAndDilutedSharesOutstanding	9419660	shares
	zivo	Weighted Average Stock Basic And Diluted Shares Outstanding WeightedAverageStockBasicAndDilutedSharesOutstanding	9419660	shares
	zivo	Weighted Average Stock Basic And Diluted Shares Outstanding WeightedAverageStockBasicAndDilutedSharesOutstanding	9419660	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4584518	usd
CY2022Q2	zivo	Employee And Director Equity Based Compensation EmployeeAndDirectorEquityBasedCompensation	497744	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2071839	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3010423	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1741662	usd
CY2023Q2	zivo	Employee And Director Equity Based Compensation EmployeeAndDirectorEquityBasedCompensation	227808	usd
CY2023Q2	zivo	Warrants Issued With Related Party Note WarrantsIssuedWithRelatedPartyNote	439594	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2070572	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3144832	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6042209	usd
	zivo	Employee And Director Equity Based Compensation EmployeeAndDirectorEquityBasedCompensation	1068373	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4100159	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3010423	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10622	usd
	zivo	Employee And Director Equity Based Compensation EmployeeAndDirectorEquityBasedCompensation	469911	usd
	zivo	Warrants Issued With Related Party Note WarrantsIssuedWithRelatedPartyNote	439593	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4043714	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3144832	usd
	us-gaap	Profit Loss ProfitLoss	4043714	usd
	us-gaap	Profit Loss ProfitLoss	4100159	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	44041	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	41297	usd
	zivo	Amortization Of Deferred Rd Obligations Participation Agreements AmortizationOfDeferredRDObligationsParticipationAgreements	-434430	usd
	zivo	Amortization Of Deferred Rd Obligations Participation Agreements AmortizationOfDeferredRDObligationsParticipationAgreements	-407085	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	214913	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	zivo	Employee And Director Equity Compensations Operating Activety EmployeeAndDirectorEquityCompensationsOperatingActivety	469911	usd
	zivo	Employee And Director Equity Compensations Operating Activety EmployeeAndDirectorEquityCompensationsOperatingActivety	1068373	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	406592	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	459036	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	474325	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-246495	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47570	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-17598	usd
	zivo	Increase In Security Deposits IncreaseInSecurityDeposits	0	usd
	zivo	Increase In Security Deposits IncreaseInSecurityDeposits	-29058	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2956	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	617432	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17616	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3114640	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4167377	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	605600	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	628600	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	269156	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	279378	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1000000	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1336444	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	349222	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1778196	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3818155	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1799263	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8901875	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21067	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5083720	usd
	us-gaap	Interest Paid Net InterestPaidNet	7131	usd
	us-gaap	Interest Paid Net InterestPaidNet	4853	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023Q2	zivo	Accumulated Deficit AccumulatedDeficit	119848244	usd
	zivo	New Accounting Standards NewAccountingStandards	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 2 - NEW ACCOUNTING STANDARDS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. The Company adopted ASU 2020-06 effective January 1, 2023, using the modified retrospective approach. The adoption of AASU 2020-06 did not have an impact on any amounts recorded the Company's condensed consolidated financial statements. In addition, the adoption requires the use of the if-converted method for all convertible notes in the diluted net income (loss) per share calculation and the inclusion of the effect of potential share settlement of the convertible notes, if the effect is more dilutive. There was no impact to diluted earnings per share for the three and six months ended June 30, 2023, as the convertible debentures were not in the money during the period.</p>
CY2023Q2	zivo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Ca ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossCA	65268	shares
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	227808	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	497744	usd
	zivo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Ca ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossCA	65268	shares
	zivo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Ca ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossCA	165000	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	469911	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1068374	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1228	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	zivo	Expected Term During Period ExpectedTermDuringPeriod	P5Y3M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0388	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1228	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.3018	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	zivo	Expected Term During Period ExpectedTermDuringPeriod	P5Y3M18D
	zivo	Expected Term During Period ExpectedTermDuringPeriod	P5Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0388	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0188	pure
CY2020Q4	zivo	Lease Agreement Term LeaseAgreementTerm	25 ½ month
CY2020Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	54993	usd
CY2020Q4	zivo	Operating Lease Commencement Date OperatingLeaseCommencementDate	2021-02-01
CY2020Q4	zivo	Rent Description RentDescription	Rent is $3,291 per month from January 15, 2021 to January 31, 2022 and $1,154 from February 1, 2022 to January 31, 2023. On June 5, 2022, the Company exercised an option to extend the lease through December 31, 2024. The lease extension rent is $2,261 per month for calendar year 2023, and $2,300 per month for calendar year 2024, and totals an additional rent obligation of $54,743 of rent over the extension period.
CY2022Q1	zivo	Lease Agreement Term LeaseAgreementTerm	34-month
CY2022Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	232464	usd
CY2022Q1	zivo	Operating Lease Commencement Date OperatingLeaseCommencementDate	2022-04-29
CY2022Q1	zivo	Rent Description RentDescription	Rent is $7,265 per month from commencement to November 30, 2022, $7,466 from November 30, 2022 to November 30, 2023, and $7,668 from November 30, 2023 to the lease end date.
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	145241	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	189282	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	106687	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99259	usd
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	50920	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	105918	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	157607	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	205177	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	27236	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	27147	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	54471	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	47291	usd
	zivo	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P1Y5M19D
CY2022	zivo	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P1Y11M8D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1100	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1100	pure
	zivo	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	57433	usd
	zivo	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	23592	usd
	zivo	Non Cash Investment In Rou Asset NonCashInvestmentInRouAsset	0	usd
	zivo	Non Cash Investment In Rou Asset NonCashInvestmentInRouAsset	241694	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	58776	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	112407	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	171183	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13576	usd
CY2023Q2	zivo	Present Value Of Future Minimum Lease Payment Sale Leaseback Transactions PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions	157607	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	106687	usd
CY2023Q2	zivo	Operating Lease Liability Noncurrent1 OperatingLeaseLiabilityNoncurrent1	50920	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.11
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2023Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0373	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.9989	pure
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1000000	usd
	zivo	Less Unamortized Debt Discount LessUnamortizedDebtDiscount	-224680	usd
	zivo	Carrying Value Of Term Loan CarryingValueOfTermLoan	775320	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	zivo	Description Of Sale Of Common Stock DescriptionOfSaleOfCommonStock	Company sold 1,030,000 shares of common stock, par value $0.001 per share, at an offering price of $2.67 per share, and pre-funded warrants at an offering of $2.6699 per pre-funded warrant to purchase up to an aggregate of 468,130 shares of Common Stock, to a single institutional investor

Files In Submission

Name	View Source	Status
0001654954-23-010769-index-headers.html	Edgar Link	pending
0001654954-23-010769-index.html	Edgar Link	pending
0001654954-23-010769.txt	Edgar Link	pending
0001654954-23-010769-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zivo-20230630.xsd	Edgar Link	pending
zivo_10q.htm	Edgar Link	pending
zivo_ex311.htm	Edgar Link	pending
zivo_ex312.htm	Edgar Link	pending
zivo_ex321.htm	Edgar Link	pending
zivo_ex322.htm	Edgar Link	pending
zivo-20230630_cal.xml	Edgar Link	unprocessable
zivo-20230630_def.xml	Edgar Link	unprocessable
zivo-20230630_pre.xml	Edgar Link	unprocessable
zivo-20230630_lab.xml	Edgar Link	unprocessable
zivo_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZIVO
Zivo Bioscience, Inc. Stock $zivo

2023 Q3 Form 10-Q Financial Statement

#000165495423010769 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZIVO Zivo Bioscience, Inc. Stock $zivo

2023 Q3 Form 10-Q Financial Statement

#000165495423010769 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZIVO
Zivo Bioscience, Inc. Stock $zivo